Australia AICIS vs US MoCRA vs EU CPNP: Where Should Korean K-Beauty Register First in 2026?

An indie Korean K-beauty founder in New York asked me last week whether Australia was easier to enter than the US. Behind the question was a real financial calculation: the founder had a 6,000-unit run leaving Incheon in October and needed to know which regulator to file with first so cash could recycle back into the next production run. This guide is the answer, written to the public record so any indie founder can use the same framework.

Australia's chemical regulator (AICIS), the US Federal Food, Drug, and Cosmetic Act as amended by MoCRA, and the EU Cosmetic Products Notification Portal (CPNP) each treat a Korean cosmetic differently. Fee structures, ingredient rules, timelines, and documentation depth vary enough that picking the wrong first market can cost a small brand a full quarter of runway. Below is the 2026 side-by-side comparison, with public citations, that Korean ODM sourcing teams and their US-based indie brand partners should use before wiring the first customs deposit.

What Is AICIS, and Why Does Australia Handle Cosmetic Chemicals Differently from the US and EU?

AICIS is the Australian Industrial Chemicals Introduction Scheme, the national regulator that manages the introduction (import or manufacture) of industrial chemicals into Australia, including chemicals used in cosmetics. AICIS replaced the older NICNAS scheme in 2020 and operates under the Industrial Chemicals Act 2019 (industrialchemicals.gov.au).

Unlike the US and EU, Australia does not run a dedicated cosmetics regulator; it regulates the ingredients themselves. Every business that imports or manufactures cosmetic chemicals must register with AICIS as an "introducer" and then categorise every introduction into one of five tiers (Listed, Exempted, Reported, Assessed, Commercial Evaluation), each with its own reporting and fee obligations (AICIS category guidance). Finished cosmetic products that also make therapeutic claims (SPF sunscreen, anti-dandruff, acne treatment) fall additionally under the Therapeutic Goods Administration (TGA) as therapeutic goods.

For a Korean ODM shipping a standard leave-on serum with no therapeutic claim, the practical requirement is registration as an introducer, a pre-introduction check on the ingredient list against the AICIS Inventory, and a categorisation for each chemical. There is no dossier deposit into a central portal in the way EU CPNP works. This is the first structural difference an indie founder needs to internalise.

How Does US MoCRA Compare to AICIS and CPNP for Korean K-Beauty Founders?

MoCRA (the Modernization of Cosmetics Regulation Act of 2022) is the US federal law that requires cosmetic facility registration and product listing with the FDA. MoCRA is administered by the FDA Office of Cosmetics and Colors, and its major requirements took effect in 2024 with ongoing enforcement expansion through 2026 (FDA MoCRA overview).

The core MoCRA obligations for a Korean K-beauty product entering the US are: (1) the manufacturing facility (usually the Korean ODM) must submit a facility registration; (2) the responsible person (usually the US-based brand) must submit a product listing for every cosmetic product; (3) safety substantiation records must be kept and produced on request; (4) adverse event reports must be filed within 15 business days for serious events; and (5) fragrance allergen labeling rules phase in over 2026 (FDA registration and listing rule). There is no pre-market approval and no FDA-issued number confirming individual product safety; MoCRA is a listing regime, not a licensing regime.

The contrast with AICIS is stark. MoCRA lists finished products; AICIS lists chemicals. The contrast with CPNP, discussed next, is also sharp: CPNP requires a Cosmetic Product Safety Report (CPSR) signed by a qualified safety assessor before a single unit ships, while MoCRA lets the product ship once the listing is filed and the brand keeps the safety file on record.

What Does EU CPNP Registration Actually Require from a Korean ODM Product?

CPNP is the Cosmetic Products Notification Portal maintained by the European Commission under Regulation (EC) No 1223/2009. Every cosmetic product placed on the EU market must be notified in CPNP by the Responsible Person, who must be established in the EU (EU CosIng and CPNP framework).

The EU regime is the most documentation-heavy of the three. Before a product can be notified on CPNP, the Responsible Person must compile a Product Information File (PIF) that includes the qualitative and quantitative formula, the manufacturing method and confirmation of Good Manufacturing Practice (typically ISO 22716), physicochemical and microbiological specifications, stability data, safety assessments for each ingredient, and a full Cosmetic Product Safety Report signed by a safety assessor holding a recognised pharmacy, toxicology, or medicine qualification (EU Cosmetic Regulation guidelines). The Responsible Person must keep the PIF at its EU address and make it available to national market surveillance authorities within 72 hours of request.

For a Korean ODM product being sold by a US indie brand into the EU, this usually means contracting an EU-based Responsible Person (many specialised firms in Ireland, the Netherlands, and Germany offer this service), sending them the Korean ODM's stability, microbiology, and challenge test results, and paying for a safety assessor to write the CPSR. It is expensive and slow relative to MoCRA. It also produces something MoCRA and AICIS do not: a document trail that satisfies most other regulators globally, which is why some founders file CPNP first even when the EU is not their target market.

How Much Does Each Regulator Cost, and How Long Does Registration Take?

Registration cost and timeline are the numbers indie founders actually want. Public fee schedules and processing time estimates from each regulator's own website give the following picture for a single-product introduction by a small brand in 2026.

AICIS annual registration for a "very small introducer" (annual value under AUD 500,000) is AUD 111 for 2025-26, plus category-specific reporting obligations (AICIS registration fees). Most cosmetic chemicals fall into the "Listed" or "Exempted" categories, which have low or no per-introduction fees but do require the introducer to run and document a pre-introduction check. Ingredient categorisation and record-keeping typically take a week of work for a small SKU count if the ODM has clean documentation ready.

MoCRA facility registration and product listing carry no fee for the initial submissions to FDA as of 2026 (FDA how-to guidance). What costs money is the safety substantiation file the brand must be prepared to produce on request, which typically means paying a consulting toxicologist a few hundred to a few thousand dollars per formula depending on complexity. Filing itself is a two-to-four hour task if the ODM COA and specification sheets are ready.

CPNP is free to submit, but a Responsible Person contract and Safety Assessor fee is the real expense: industry press reports and Responsible Person service pages document CPSR fees in the range of a few hundred to over a thousand euros per product depending on ingredient count and novelty (Cosmetics Business CPNP explainer). Preparation of the full PIF plus safety assessment typically takes four to eight weeks for a Korean-formulated product because ingredient data from the Korean ODM has to be translated and mapped to EU CosIng entries.

How Do Ingredient Rules Differ Across AICIS, MoCRA, and CPNP for Common K-Beauty Actives?

The ingredient lists a Korean ODM formulates with will not clear all three regulators the same way. Some actives are unrestricted in one regime and banned or capped in another. Founders who assume Korean approval equals global approval get expensive shipment holds.

Sunscreen UV filters are the sharpest example. Australia treats sunscreens with SPF 4+ as therapeutic goods under the TGA and requires listing on the Australian Register of Therapeutic Goods before the product can be supplied, with a restricted list of allowed UV filters (TGA sunscreens page). The EU CosIng annex permits a specific list of UV filters, and any filter not on that annex is prohibited, meaning a Korean sunscreen using a filter approved in Korea but not in the EU annex cannot ship. The US operates under a monograph system administered by the FDA that has approved fewer new UV filters than either Korea or the EU, which is why many Korean sunscreens are effectively unsellable in the US as OTC drug products (FDA sunscreen guidance).

Preservatives are another divergence. Methylisothiazolinone and methylchloroisothiazolinone are restricted differently in the EU (banned in leave-on products since 2017 per EU Regulation 2016/1198) than in the US and Australia, where formulations using them within concentration limits remain permitted. Korean formulas frequently use preservative systems that need reformulation for the EU market even when the finished product passes Korean stability testing.

Peptides, fermented ingredients, and centella-based extracts (staples of K-beauty) are generally acceptable across all three regimes but require careful INCI naming. AICIS requires each chemical to appear on the AICIS Inventory or be introduced under a categorisation pathway; ingredients derived from novel fermentation strains sometimes fall outside the Inventory and need Assessed introductions, which are the slowest AICIS category.

The framework to walk through, for any ingredient on a Korean COA: check the EU CosIng entry, check the FDA voluntary cosmetic ingredient review (CIR) status, check the AICIS Inventory, and flag any restricted-concentration or annex-listed entries for reformulation before shipping.

I'm Liz, I run ALTA MEET from Manhattan, NYC. I help indie K-beauty founders map their Korean ODM formulas to the regulator most likely to clear them first, without paying for three parallel dossiers. If you want a quick gut-check on whether Australia, the US, or the EU is your best 2026 entry market, I'll give you 15 minutes free. Book via calendly.com/liz-altameet/gut-check or email liz@altameet.com.

Side-by-Side Comparison of AICIS, MoCRA, and CPNP for a Standard Korean K-Beauty Serum

The table below summarises the practical differences a founder is trading off. Values are for a hypothetical vitamin-C-plus-hyaluronic-acid serum manufactured by a Korean ODM and imported by a small US-based brand entering each market in 2026.

Which Market Should an Indie Korean K-Beauty Founder Register First in 2026?

The right first market depends on where the demand is, not where the paperwork is easiest. But the paperwork does matter for cash flow, and the answer is more nuanced than "always start with the US."

Start with MoCRA if the primary revenue channel is a US retailer, Amazon US, or a US-focused DTC storefront. MoCRA is the cheapest and fastest to file, and the safety file the brand builds satisfies the discovery-style requests US retailers make during buyer onboarding. This is the path most indie K-beauty founders take.

Start with AICIS if the founder already has an Australian retail partner (David Jones, Mecca, Adore Beauty, an Australian pharmacy chain) or a Sydney-based agent lined up. Registration is cheap and quick, and the AICIS Inventory categorisation forces the founder to review the formula ingredient-by-ingredient, which is useful diligence. Do not start with AICIS if the product is a sunscreen or makes therapeutic claims; the TGA pathway is a separate and much heavier lift.

Start with CPNP if the founder wants a "gold standard" dossier before entering any Western market and can afford the four-to-eight-week PIF preparation window. The safety file that comes out of a CPNP submission is the most portable of the three and reduces friction when later filing MoCRA, AICIS, UK SCPN, Health Canada CNF, or MFDS-related documentation for cross-border Korean exports (see our Canada CNF vs FDA MoCRA guide). Founders selling premium-priced serums to specialty European retailers often take this route.

The trap to avoid: filing MoCRA quickly, shipping into the US, then discovering the same formula cannot legally enter the EU because a preservative or UV filter needs reformulation. A one-hour ingredient audit against EU CosIng before finalising the Korean ODM formula would have surfaced the problem for a fraction of a re-run's cost.

What Should a Korean ODM Deliver to Make Any Regulator Filing Easier?

Whichever regulator the brand files with first, the Korean ODM has to hand over the same core artefacts. The ODM that already has these ready is the ODM worth working with; the one that scrambles for them after the PO is a warning sign.

The regulator-agnostic ODM document pack includes: a full quantitative INCI formula in both Korean and English, batch-specific certificates of analysis for the finished product and each raw material, a stability study report per ICH Q1A or ISO 11930 conditions, a preservative efficacy test (PET) per ISO 11930, a challenge test result, a heavy metals and microbiology specification sheet, an ISO 22716 GMP certificate for the manufacturing facility, and, for skin-contact products intended for the EU, ready-to-supply toxicological profiles for each ingredient. Every one of these is a public-record best-practice line item derived from the EU Cosmetic Regulation and the ISO standards it references.

For founders comparing Korean ODMs, our complete K-beauty founder step-by-step guide lays out the wider sourcing framework, and our FDA Korean skincare import guide deep-dives the MoCRA-specific pieces of the pack. Founders also comparing regulator cost stacks should consult our cost-to-manufacture-in-Korea guide, since the ODM production quote itself dwarfs any regulator fee for most launch runs.

FAQ: Common Questions About Registering Korean K-Beauty Across Australia, US, and EU

Do I need a local business entity in Australia to register with AICIS? You need an Australian-registered introducer, which can be your own Australian subsidiary, an Australian distributor acting as importer of record, or a service provider offering agent-of-record introduction services. AICIS itself does not require the introducer to be Australian-owned, only Australian-registered under an ABN (Australian Business Number).

Can one CPNP notification cover the entire EU plus the UK? No. Since Brexit, the UK operates its own Submit Cosmetic Product Notifications (SCPN) portal separate from CPNP. A Korean K-beauty product sold in both the EU and UK needs two parallel notifications, each with its own Responsible Person, though the underlying PIF and CPSR can be reused with jurisdiction-specific labeling adaptations.

Is MoCRA enforcement actually happening or is it still a soft launch in 2026? FDA has been publishing enforcement guidance and continues to phase in requirements. Facility registration and product listing are now expected of all cosmetic products marketed in the US. Serious adverse event reporting is enforceable now, and fragrance allergen labeling phases in through 2026. Small businesses (defined by MoCRA as those with average gross annual sales under one million USD) are exempt from facility registration and product listing but still subject to safety substantiation and adverse event reporting.

Do Korean OEM/ODM factories usually already have facility registration with FDA or a Responsible Person set up for the EU? The larger Korean ODMs (Cosmax, Kolmar Korea, Kolmar BNH, Cosmecca, and their tier-one peers) typically hold current FDA facility registrations because they manufacture for US-based clients at scale. Mid-tier ODMs may or may not; ask for the FDA facility identifier during quote review. For EU Responsible Person, the ODM does not usually fill that role; the brand or its EU distributor does.

If I have to pick only one regulator to file with in Q1 2026 due to budget, which is safest? MoCRA. It is the cheapest, fastest, and covers the biggest single K-beauty market. As long as you keep a documented safety file and prepare adverse event reporting workflows, MoCRA gets the product legally on shelves in the US within weeks. Filing AICIS or CPNP later, when there is a specific Australian or European buyer, is a reasonable sequencing.

Key Takeaways for Korean K-Beauty Indie Founders

AICIS, MoCRA, and CPNP are three different regulatory architectures, not three flavours of the same thing. AICIS regulates chemicals, MoCRA lists products, and CPNP demands a full safety dossier. Fees are low across all three; the real cost is documentation preparation and, for CPNP, the safety assessor. For most US-focused indie K-beauty founders in 2026, MoCRA first is the cash-efficient answer. For Australia-focused or EU-focused launches, AICIS and CPNP each have their own logic, and the wrong pick can waste a quarter of runway on the wrong dossier.

The Korean ODM document pack is regulator-agnostic. Build it once, use it across all three regimes. And do the ingredient audit against EU CosIng before you finalise the formula, even if your first market is the US; retrofitting a K-beauty formula for the EU annexes is the single most avoidable cost in cross-border cosmetics.

Need help mapping your Korean ODM formula to the right first regulator? Book a free 15-minute gut-check at calendly.com/liz-altameet/gut-check or email liz@altameet.com. Partnership inquiries: partnerships@altameet.com.

By the ALTA MEET editorial team | K-beauty ODM consulting. Reviewed for accuracy by ALTA MEET's formulation consulting team.